suicide

Ties Between Illicit Drug Use and Youth Suicidality

CRAZY TIMES –

May 26, 2022 – The investigational schizophrenia treatment xanomeline/trospium (KarXT) yielded significantly greater improvements in all five Positive and Negative Syndrome Scale (PANSS) Marder factors versus placebo, according to the phase II EMERGENT-1study. These improvements were significant by week 2 of treatment, and included positive and negative symptoms, disorganized thought, uncontrolled hostility, and depression/anxiety.

In the 5-week randomized trial among 170 inpatients with schizophrenia, those treated with a maximum of 125 mg/30 mg twice daily also had significant improvements in Clinical Global Impressions Scale categorical responses as early as week 2 of treatment.

“If confirmed in ongoing phase 3 studies and approved by the [FDA], KarXT may represent a novel class of treatment for patients with schizophrenia based on muscarinic receptor agonism,” Christoph Correll, MD, of the Zucker Hillside Hospital in Glen Oaks, New York, and colleagues said in an APA poster.

more@MedPageToday

Leonard Buschel

Recent Posts

An Interview with NuQI’s John Wright

EMR MATTERS – October 2024 - The challenge is that many in the behavioral health…

3 days ago

California Wants Social Media To Have ‘black box warning’ For Kids

TOO LITTLE, TOO LATE? – Dec. 19, 2024 - Assembly Bill 56 (AB 56) proposes…

6 days ago

Lily Allen Shares the Moment She Hit ‘Rock Bottom’

AND STOPPED DIGGING – Dec. 4, 2024 - In a new interview with The Times,…

6 days ago

170 Million Americans Learn Deadly Toxin is Toxic

NOT JUST IN PENCILS – Dec. 8, 2024 - Americans born before 1966 experienced “significantly…

6 days ago

Famous Child Star After Opening Up About Addiction

AS SUCCESSFUL AS EVER – Dec. 3, 2024 - Family Affair actor Johnny Whitaker looked…

6 days ago

Top 10 Things Families Can Do to Avoid Common Rehab Pitfalls

ALANON Plus – Dec. 7, 2024 - A high percentage of treatment failures occur due…

6 days ago